Hariri Susan, Dunne Eileen F, Sternberg Maya, Unger Elizabeth R, Meadows Kristi S, Karem Kevin L, Markowitz Lauri E
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.
Sex Transm Dis. 2008 Mar;35(3):298-303. doi: 10.1097/OLQ.0b013e31815abaef.
The national seroprevalence of the nononcogenic human papillomavirus (HPV) type 11, one of the types targeted by the quadrivalent HPV vaccine, has not been evaluated in the United States. The objectives of this study were to estimate the national seroprevalence and evaluate predictors of HPV-11 seropositivity.
We tested serum samples for HPV-11 antibodies and analyzed questionnaire data from the second phase of the National Health and Nutrition Examination Survey III, 1991--1994. Seroprevalence estimates were weighted to represent the US population.
: Overall seroprevalence of HPV-11 infection was 4.7%. Seroprevalence was significantly higher among females (5.7%) than among males (3.6%). Independent predictors of HPV-11 seropositivity included sex, race/ethnicity, lifetime number of sex partners, education, and HPV-16 seropositivity.
This study represents the most comprehensive picture of HPV-11 infection in the United States to date, and provides baseline data on the prevalence of HPV-11 before availability of the quadrivalent HPV vaccine.
四价人乳头瘤病毒（HPV）疫苗的目标类型之一——非致癌性HPV11型在美国的全国血清阳性率尚未得到评估。本研究的目的是估计全国血清阳性率并评估HPV-11血清阳性的预测因素。
我们检测了血清样本中的HPV-11抗体，并分析了1991年至1994年第三次全国健康和营养检查调查第二阶段的问卷数据。血清阳性率估计值经过加权以代表美国人群。
HPV-11感染的总体血清阳性率为4.7%。女性（5.7%）的血清阳性率显著高于男性（3.6%）。HPV-11血清阳性的独立预测因素包括性别、种族/民族、终身性伴侣数量、教育程度和HPV-16血清阳性。
本研究代表了迄今为止美国HPV-11感染的最全面情况，并提供了四价HPV疫苗上市前HPV-11流行率的基线数据。
